Primary Objectives:~To estimate disease control rate (DCR) in patients with metastatic, recurrent, or persistent cervical cancer who have not received prior systemic chemotherapy and are undergoing induction immunotherapy with MGD019.~Secondary Objectives:~To determine overall survival (OS)~To determine progression-free survival (PFS)~To determine objective response rate (ORR)~To determine duration of response (DOR)~To evaluate safety of administering MGD019 in cervical cancer patients using the National Institute of Health Common Terminology Criteria for Adverse Events (CTCAE) v5.0~Exploratory Objectives:~To investigate molecular and immunological changes in the tumor tissue prior to and on-treatment with MGD019~To identify treatment-induced tissue-based alterations in malignant and immune cells and their correlation with response, progression, and immune-related adverse events~To determine the utility of cell-free DNA for evaluation treatment response
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.